Pherecydes Pharma announces the creation of an international Medical Advisory Board










Photo credit © Reuters


(Boursier.com) – Pherecydes Pharma, a biotechnology company specialized in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the formation of a Medical Advisory Board, consisting of scientific and clinical experts who lead companies international specialized in infection. .

“We are happy and honored to be able to cooperate with this internationally renowned group of scientists,” said Didier Hoch, CEO of Pherecydes Pharma.

The members of the Medical Advisory Board are: Dr. Saima Aslam, Associate Professor of Infectious Medicine at UC San Diego, California, USA.
Professor Marc Bonten, Chair of the Strategic Research Program “Infection and Immunity” at the UMC in Utrecht, the Netherlands.
Pr Tristan Ferry, Deputy Head of Service in the Infectious and Tropical Diseases Service of HCL Lyon and President of the National Scientific Committee of CRIOACs, France.
Prof. Yok-Ai Que, Associate Professor of Intensive Care Medicine at Bern Hospital, Switzerland.
Prof. Martin Witzenrath, Director of the Department of Respiratory Diseases and Intensive Care at Charité-Universitätsmedizin Berlin, Germany.

Next financial publication with the results of the half of the year 2022, Thursday, October 27, 2022, after the market.


©2022 Boursier.com




Leave a Comment

Your email address will not be published.